A study on SCLC therapy has demonstrated that DNA damage response (DDR) inhibitors suppress PD-L1-induced immunosuppression by enhancing the expression of Cxcl10 and Ccl5 in the STING/TBK1/IRF3 pathway [48]. Here, IRF3 is linked to small cell lung carcinoma.